EDSA 100% gain21 Sep 2021 08:42
Edesa Biotech jumps up 102% after positive phase 2 data for its Monoclonal antibody covid treatment.
The potential is out there. Seems to me the BOD wants to get over to Nasdaq prior to such trial news, so that gains can be solidified rather than the mess of being across two markets.